Back to results

University of Pretoria

South Africa's national health reform : how leading R&D pharmaceutical companies are responding

Abstract

dc:description.abstract

In December 2015, the South African government released the much anticipated White paper on the planned National Health Insurance (NHI) (Department of Health, 2015) raising more questions ("NHI White Paper", 2016) amongst stakeholders. Frost and Sullivan (2011) have suggested that the planned cost containment of the NHI will benefit generic companies whilst research and development (R&D) companies, the biggest upstream providers in the private healthcare sector in South Africa, might consider pulling out of the country. In order to ensure long-term sustainable growth within the new NHI landscape, R&D pharmaceutical companies will have to align their strategic approach to meet several stakeholder demands in this changing environment. Therefore, this study's primary objective was to investigate the behavioural tactics of R&D pharmaceutical companies in response to the NHI, viewed from their perspectives as the change recipients. An in-depth exploratory qualitative research design was employed as the researcher was concerned not only with how these pharmaceutical companies are preparing for the NHI, but also with the rationale underpinning those selected change tactics employed by R&D pharmaceutical companies. A total of five, highly experienced senior executives, representing leading R&D pharmaceutical companies, were interviewed. Findings from this research revealed several important themes, from the need for diversified pharmaceutical portfolios in order to address the country's disease burden, to improved market access and public-private partnerships to overcome current challenges. However, throughout this research project, the importance of extensive stakeholder engagement, particularly from the government, was identified as both a barrier and enabler to the successful implementation of the NHI.

Degree

thesis:*
Grantor dc:publisher
University of Pretoria
Year dc:date.issued
2017

Author and committee

dc:creator, dc:contributor.*
Advisor dc:contributor.advisor
  • Cajee, Zaheeda

Subjects

dc:subject × 1

Rights

dc:rights
Statement dc:rights
  • © 2017 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria.
Language dc:language.iso
en

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/2263/59838
OAI identifier oai:identifier
oai:repository.up.ac.za:2263/59838

Chain of custody

source
Harvested from
University of Pretoria
Base URL
repository.up.ac.za/server/oai/request
Last updated
2026-07-24
Source record
OAI-PMH GetRecord
related terms
citation

South Africa's national health reform : how leading R&D pharmaceutical companies are responding. University of Pretoria, 2017. http://hdl.handle.net/2263/59838